ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2025
Burden of Nonmalignant Liver and Pancreatic Diseases in the United States Population: Rates and Trends.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nonmalignant liver and pancreatic diseases are common in the United States and lead to significant morbidity, mortality, and health care utilization. We used national survey and claims databases to investigate rates and trends in the liver and pancreatic disease burden over the past decade in the United States. The Nationwide Emergency Department Sample, National Inpatient Sample, Vital Statistics of the United States: Multiple Cause-of-Death Data, Optum Clinformatics Data Mart, and Centers for Medicare and Medicaid Services Medicare 5% Sample and Medicaid files were used to estimate claims-based prevalence, medical care use, and mortality with an all-listed liver or pancreatic disease diagnosis. In the US population, liver disease contributed to 2.7 million emergency department visits, 2 million hospital stays, and 134,000 deaths in 2021. Pancreatitis was a less common but still significant cause of health care use contributing to 733,000 emergency department visits, 552,000 hospital stays, and 9000 deaths in 2021. For both conditions, male and American Indian/Alaska Native persons had a greater mortality and medical care use burden. During the study period, both medical care use and mortality rates with a liver disease diagnosis rose, concerningly reversing previously declining trends. For pancreatitis, medical care use rates stabilized or declined during recent years and the mortality rate declined through 2019 and then rose through 2021. The burden of nonmalignant liver and pancreatic diseases in the United States is substantial. The rise in liver disease mortality rates following the reversal of a previous downward trend is particularly concerning. Hence ongoing surveillance of liver disease and pancreatitis prevalence may better inform research programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.